The global next-generation antibody therapy market is expected to reach approximately $18.86 billion by 2025 and is expected to reach $74.3 billion by 2032, with a CAGR as high as 21.6%. Traditional monoclonal antibodies still form the core market, but generic drug growth (18%–28%) far exceeds the overall market, forcing innovation and upgrading.

The trillion-yuan track has a high base growth

The global antibody drug market is expected to continue strong growth through 2025. According to Fact.MR data, the global antibody market is expected to be worth approximately $240 billion by 2025 and is expected to reach $460 billion by 2035, with a compound annual growth rate of 6.7%.

Traditional monoclonal antibodies remain the market foundation, but growth elasticity has significantly shifted toward next-generation antibody therapies. The global monoclonal antibody market is expected to reach approximately USD 234.3 billion in 2024 and increase to approximately USD 261.7 billion by 2025, with a CAGR of about 11.6%. However, the growth rate of monoclonal antibody generics (18%–28%) far exceeds the overall monoclonal antibody market, and Frost & Sullivan expects that the future growth focus of the antibody market will gradually shift from traditional monoclonal antibodies to new structural antibodies with more complex mechanisms and higher barriers.

AI is upgrading from an "auxiliary tool" to a "core engine"

Global AI in the antibody discovery market is valued at approximately $530 million by 2025 and is expected to reach $4.84 billion by 2035, with a CAGR as high as 24.76%. Among them, the AI-designed antibody segment is valued at about $436 million by 2025 and is expected to reach $1.908 billion by 2032, with a CAGR of about 23.2%.

From a broader perspective of the overall antibody discovery market, it is estimated at approximately $11.15 billion by 2025 and is expected to reach $35.35 billion by 2035, with a CAGR of 12.23%. AI is significantly shortening R&D cycles, improving success rates, and reducing costs through structural prediction, epitope prediction, de novo design, and affinity maturity. Antibody discovery is moving from a high-investment, high-risk "trial-and-error model" to a predictable and optimized "compute-driven model."

China's Power: From "Bringing In" to "Exporting"

China's antibody drug industry is currently in a historic leap forward. China's monoclonal antibody market is projected to reach a CAGR of 31.4% from 2021 to 2024, with an expected size of 165.3 billion yuan in 2025 and a potential surpassing 197.1 billion yuan in 2026. Globally, China's antibody market growth rate far exceeds that of Europe and the US, expected to reach $25.97 billion by 2025 and $94 billion by 2035, with a CAGR of 13.7%.

BD going global has become the core channel for Chinese innovative pharmaceutical companies to realize their value. The total licensed transaction value for China's innovative drugs surged from $2.562 billion in 2017 to $140.274 billion by 2025, marking an exponential leap. In 2025, a total of 157 external licensing transactions will be completed, with down payments reaching $7 billion, totaling approximately $135.7 billion. BD momentum accelerated even further at the start of 2026, with total external licensing transactions exceeding $60 billion in Q1, nearly half of the total for the entire year of 2025.

Domestic and international demand resonates, and the inflection point for CDMO orders has emerged. China's CXO market is expected to reach about 210 billion yuan in 2024 and is expected to exceed 270 billion yuan by 2026. Service providers deeply bound to ADCs and dual antibody tracks directly benefit from high outsourcing rates and the growth of downstream BD. AI and automation are reshaping the standards for R&D outsourcing services, further reducing costs and increasing efficiency.

Emerging Leader in Automated Gene Services—GentleGen

GentleGen is the first domestic gene technology platform to achieve end-to-end automated large-scale application, centered on "automation + intelligence," building a one-stop solution covering gene synthesis, sequencing, editing, and expression.

• Core Technology Platform: Relying on its self-built GentSynExp 3.0 G-Lab fully automated gene antibody platform, the company adopts a "black factory" modular production model, integrating automated hardware systems, AI algorithms, and information management platforms to achieve full-chain unmanned production from gene design to plasmid delivery

• Efficiency and Quality Advantages: From gene synthesis to antibody supernatant in as little as 7–10 days, shortening the industry average cycle by more than 50%; Clone vector delivery takes as little as 72 hours, and transfection-grade plasmid preparation can be completed in just 3 working days. The platform can process 3000+ samples in a single run, with daily reaction volumes exceeding 5000+. The company has launched a new generation of bispecific antibody expression services, shortening delivery cycles to 3 weeks, with SEC-HPLC purity reaching over 95%.

• Safety Evaluation and Market Collaboration: Leveraging its advanced NGS technology platform, GentleGen has launched safety evaluation solutions for recombinant protein/antibody drugs, covering monoclonal origination testing, genetic stability testing, and integrated locus analysis, providing reliable data support for pharmaceutical companies from cell line construction to process development and clinical submission.

GentleGen can provide related genetic technology services. For detailed information about related services, please send an email to marketing@gentlegen.com.